{"log_id": 2613985951937669180, "direction": 0, "words_result_num": 41, "words_result": [{"probability": {"variance": 2e-05, "average": 0.996361, "min": 0.990104}, "location": {"width": 60, "top": 149, "height": 23, "left": 218}, "words": "的标准"}, {"probability": {"variance": 8.5e-05, "average": 0.994382, "min": 0.948267}, "location": {"width": 734, "top": 159, "height": 43, "left": 233}, "words": "失访(在100天内未接受观察)并且未满足另一项临床失败终点的患者。这些患者被视"}, {"probability": {"variance": 0, "average": 0.999976, "min": 0.999976}, "location": {"width": 29, "top": 155, "height": 64, "left": 1124}, "words": "食"}, {"probability": {"variance": 2e-06, "average": 0.9972, "min": 0.995987}, "location": {"width": 60, "top": 204, "height": 25, "left": 218}, "words": "为失败"}, {"probability": {"variance": 0, "average": 0.979374, "min": 0.979374}, "location": {"width": 22, "top": 233, "height": 25, "left": 1130}, "words": "付"}, {"probability": {"variance": 8e-06, "average": 0.99797, "min": 0.985912}, "location": {"width": 740, "top": 271, "height": 42, "left": 259}, "words": "总之,进行了2项预防性临床研究。如表格中所示(表6和表7),临床失效作为复合终"}, {"probability": {"variance": 0.002182, "average": 0.989991, "min": 0.696628}, "location": {"width": 779, "top": 311, "height": 41, "left": 221}, "words": "点,包括突破性侵袭性真菌感染、死亡和使用全身抗真菌治疗。在研究1(表6)中,泊沙康"}, {"probability": {"variance": 0.005675, "average": 0.969189, "min": 0.633571}, "location": {"width": 799, "top": 350, "height": 43, "left": 221}, "words": "唑(33%)与氟康唑(37%)的临床失败率相似(泊沙康唑对照药物差异的95%置信区间11.5%"}, {"probability": {"variance": 0.000409, "average": 0.990667, "min": 0.89547}, "location": {"width": 778, "top": 388, "height": 44, "left": 223}, "words": "至3.7%)。而在研究2(表7)中,接受泊沙康唑治疗的患者的临床失败率(27%)低于接"}, {"probability": {"variance": 0.004297, "average": 0.977815, "min": 0.669557}, "location": {"width": 780, "top": 428, "height": 43, "left": 222}, "words": "受氟康唑或伊曲康唑治疗的患者(42%)(泊沙康唑-对照药物差异的95%置信区间-22.9%"}, {"probability": {"variance": 0.002803, "average": 0.970772, "min": 0.842921}, "location": {"width": 81, "top": 485, "height": 22, "left": 226}, "words": "至-7.8%)"}, {"probability": {"variance": 0.00977, "average": 0.976885, "min": 0.38108}, "location": {"width": 744, "top": 507, "height": 43, "left": 262}, "words": "在研究1的2个治疗组中,第16周的所有原因的死亡率相似泊沙康唑58301(19%)与"}, {"probability": {"variance": 0.002216, "average": 0.983983, "min": 0.702034}, "location": {"width": 779, "top": 546, "height": 46, "left": 226}, "words": "氟康唑59299(20%)];在研究2中,泊沙康唑治疗组患者在第100天的所有原因的死亡率"}, {"probability": {"variance": 0.004264, "average": 0.979339, "min": 0.565609}, "location": {"width": 780, "top": 587, "height": 43, "left": 226}, "words": "低于泊沙康唑治疗组[泊沙康唑44304(14%)与氟康唑伊曲康唑64298(21%)]。2项研"}, {"probability": {"variance": 0.008196, "average": 0.980124, "min": 0.440363}, "location": {"width": 780, "top": 625, "height": 44, "left": 227}, "words": "究证明,在接受泊沙康唑预防的患者中,曲霉菌导致的突破性感染发生率低于接受氟康唑或"}, {"probability": {"variance": 2e-06, "average": 0.998712, "min": 0.996611}, "location": {"width": 186, "top": 678, "height": 30, "left": 226}, "words": "伊曲康唑治疗的患者"}, {"probability": {"variance": 0.0043, "average": 0.9675, "min": 0.749107}, "location": {"width": 267, "top": 714, "height": 33, "left": 266}, "words": "2、治疗口咽念珠菌病(OPC)"}, {"probability": {"variance": 0.001157, "average": 0.990172, "min": 0.819929}, "location": {"width": 787, "top": 743, "height": 43, "left": 270}, "words": "研究3是一项在出现口咽念珠菌病的HIV感染患者中进行的随机化、对照评估者设"}, {"probability": {"variance": 0.005642, "average": 0.977201, "min": 0.561258}, "location": {"width": 868, "top": 786, "height": 38, "left": 231}, "words": "研究。患者接受泊沙康唑或氟康唑口服混悬液治疗(泊沙康唑和氟康唑的给药方案如下所示:"}, {"probability": {"variance": 0.001076, "average": 0.980813, "min": 0.865498}, "location": {"width": 566, "top": 826, "height": 43, "left": 232}, "words": "100mg,每日2次,为期1天,之后为100mg,每日1次,为期13天"}, {"probability": {"variance": 0.000106, "average": 0.99462, "min": 0.951898}, "location": {"width": 737, "top": 864, "height": 41, "left": 275}, "words": "在为期14天的治疗后以及治疗结束后第4周,对临床和真菌学结果进行评估。至少接受1"}, {"probability": {"variance": 4.2e-05, "average": 0.997184, "min": 0.965859}, "location": {"width": 780, "top": 902, "height": 43, "left": 234}, "words": "次研究药物治疗并且基线期口腔拭子念珠菌培养阳性的患者被纳入分析(表8)。大多数受"}, {"probability": {"variance": 2e-06, "average": 0.998846, "min": 0.995413}, "location": {"width": 301, "top": 951, "height": 33, "left": 235}, "words": "试者的基线期病原体为白色念珠菌"}, {"probability": {"variance": 0.00219, "average": 0.988565, "min": 0.69982}, "location": {"width": 742, "top": 982, "height": 40, "left": 276}, "words": "在2个治疗组中,第14天的临床成功率(所有溃疡和/或菌斑以及症状完全或部分缓解)"}, {"probability": {"variance": 1.6e-05, "average": 0.997668, "min": 0.9768}, "location": {"width": 712, "top": 1023, "height": 40, "left": 239}, "words": "和治疗结束后4周的临床复发率(初始治愈或改善后,体征或症状复发)相似(表8"}, {"probability": {"variance": 0.005421, "average": 0.982213, "min": 0.545231}, "location": {"width": 737, "top": 1060, "height": 44, "left": 278}, "words": "在2个治疗组中,真菌根除率(治疗结束时,第14天的定量培养中不存在茵落形成单"}, {"probability": {"variance": 1.7e-05, "average": 0.996967, "min": 0.982705}, "location": {"width": 515, "top": 1104, "height": 38, "left": 240}, "words": "位)以及真菌复发率(治疗结束后4周)也相似(参见表8"}, {"probability": {"variance": 0.000946, "average": 0.986976, "min": 0.859161}, "location": {"width": 511, "top": 1143, "height": 36, "left": 306}, "words": "表8:口咽念珠菌病中的临床成功率、真菌根除率和复发率"}, {"probability": {"variance": 1e-06, "average": 0.99826, "min": 0.996619}, "location": {"width": 79, "top": 1188, "height": 24, "left": 620}, "words": "泊沙康唑"}, {"probability": {"variance": 0.000232, "average": 0.98704, "min": 0.965495}, "location": {"width": 59, "top": 1185, "height": 24, "left": 787}, "words": "氟康唑"}, {"probability": {"variance": 0.01083, "average": 0.961359, "min": 0.503065}, "location": {"width": 681, "top": 1207, "height": 43, "left": 251}, "words": "治疗结束时(第14天)的临床成功率155169(91.7%)148/60(925%"}, {"probability": {"variance": 0, "average": 0.939437, "min": 0.939437}, "location": {"width": 74, "top": 1181, "height": 72, "left": 993}, "words": "1"}, {"probability": {"variance": 9.1e-05, "average": 0.994, "min": 0.963306}, "location": {"width": 263, "top": 1244, "height": 31, "left": 250}, "words": "临床复发率(治疗结束后4周)"}, {"probability": {"variance": 0.003247, "average": 0.973568, "min": 0.711489}, "location": {"width": 306, "top": 1240, "height": 25, "left": 626}, "words": "5/155(29.0%)52/148(35.1%"}, {"probability": {"variance": 0.0036, "average": 0.971189, "min": 0.669773}, "location": {"width": 679, "top": 1262, "height": 43, "left": 252}, "words": "治疗结束时(第14天)的真菌根除率(不8169(52.1%)80160(50.0%)"}, {"probability": {"variance": 0.005049, "average": 0.956457, "min": 0.81489}, "location": {"width": 85, "top": 1305, "height": 23, "left": 255}, "words": "存在CFU"}, {"probability": {"variance": 2.9e-05, "average": 0.994631, "min": 0.982874}, "location": {"width": 262, "top": 1324, "height": 33, "left": 254}, "words": "真菌复发率(治疗结束后4周)"}, {"probability": {"variance": 0.018013, "average": 0.938337, "min": 0.389973}, "location": {"width": 283, "top": 1319, "height": 28, "left": 626}, "words": "488(55.6%)51/80(63.7%"}, {"probability": {"variance": 0.001764, "average": 0.986228, "min": 0.745529}, "location": {"width": 736, "top": 1378, "height": 38, "left": 284}, "words": "在2个治疗组中,真菌应答率也相似(泊沙康唑68.0%,氟康唑68.1%),其中成功标"}, {"probability": {"variance": 0.000433, "average": 0.99208, "min": 0.883393}, "location": {"width": 724, "top": 1418, "height": 39, "left": 250}, "words": "准为治疗后定量培养中菌落形成单位数≤20(CFU/mL)。这个结果的临床显著性未知"}, {"probability": {"variance": 0, "average": 0.701042, "min": 0.701042}, "location": {"width": 18, "top": 1472, "height": 18, "left": 976}, "words": "海"}], "language": 3}